SecBot SecBot
8-K ·Filed Nov 5, 2026

BRKR

BRUKER CORP
NEUTRAL
Impact 2/10
Horizonweeks Processed11d 5h ago SEC0001193125-26-449782
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Monitor upcoming 10-Q for Q3 2026 to see the first full quarter of results under the new segment structure, particularly BSI BIOS and BSI BMID margins.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$61.31
T+0 close · Nov 5, 2026 · via day close
Latest settled
+0.46%
T+5 · $61.59
Vs SPY
−2.14%
α at T+5
Next horizon
T+20
in 20d
  1. T+0 · Nov 6 $61.31entry
  2. T+1 · 8d ago +8.53%α +6.16% · $66.54
  3. T+5 · 4d ago +0.46%α −2.14% · $61.59
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Bruker filed an 8-K to disclose a reorganization of its reportable segments effective July 1, 2026, and provided recast segment financials for historical periods. The new segments are BSI BIOS, BSI Microbiology and Infection Diagnostics (BMID), BSI NANO, and BEST. The recast data does not change consolidated results.

Key Facts

  • Effective July 1, 2026, Bruker reorganized from four segments (BSI BioSpin, BSI CALID, BSI NANO, BEST) to four new segments (BSI BIOS, BSI BMID, BSI NANO, BEST).
  • BSI BIOS combines the former BioSpin, SciY, Chemspeed Technologies, Daltonics, Optics, and Mimetas divisions.
  • BSI BMID consists of the Microbiology, Molecular Diagnostics, and Biomedical Systems divisions (formerly part of BSI CALID).
  • BSI NANO and BEST segments were unchanged.
  • The recast segment information covers FY2024, FY2025, Q1-Q3 2025, and Q1-Q2 2026, with no impact on consolidated results.
  • Total consolidated revenue for the six months ended June 30, 2026 was $1,661.9 million (recast), compared to $1,598.8 million for the same period in 2025.

Financial Impact

No direct financial impact; recast data shows consolidated revenue of $1,661.9M for H1 2026 vs $1,598.8M for H1 2025, a 3.9% increase.

segment revenuesegment gross profitsegment operating income

Risk Factors

  • No material risks identified; this is a routine segment realignment disclosure.

Market Snapshot

Exchange
Nasdaq
Sector
Laboratory Analytical Instruments
Analyst Consensus
55% bullish (20 analysts)

Investment Themes

Industrials & Manufacturing

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-449782
Document: brkr-20261105.htm0001193125-26-449782
Document: 0001193125-26-449782-index-headers.html0001193125-26-449782
Document: 0001193125-26-449782-index.html0001193125-26-449782
Document: 0001193125-26-449782.txt0001193125-26-449782

US Market Status

Market Closed · Opens Wed (11h 30m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026